)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Veracyte
Veracyte (VCYT) investor relations material
Veracyte 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary15 Jan, 2026
Strategic vision and platform expansion
Focused on transforming global cancer care through advanced molecular diagnostics, broad genomic assays, and a platform approach.
Platform supports risk assessment, diagnosis, prognosis, treatment guidance, and monitoring across multiple cancer types, including urology, endocrinology, pulmonology, and women's health.
Generates more data per test than required, creating a data-driven flywheel for growth and clinical utility.
Over 800,000 patients served and 600+ supporting publications as of 2025.
International expansion and innovation are central to long-term strategy.
Financial performance and outlook
2025 revenue expected at ~$516 million, with 17% testing revenue growth, led by Afirma and Decipher.
Achieved >25% adjusted EBITDA margin in 2025, ahead of target, and aiming to maintain it in 2026.
2026 revenue guidance of $570–$582 million, with 10–13% YOY growth and 14–16% YOY testing growth.
Nearly $400 million in cash and no debt, enabling both organic and inorganic growth opportunities.
Capital allocation prioritizes high-return projects, with a disciplined approach to M&A.
Product innovation and pipeline
Decipher and Afirma remain core growth drivers, with Decipher at ~33% and Afirma at ~38% market penetration by end of 2025.
Decipher Metastatic launched; new predictive signatures (PORTOS, PTEN) to be added in 2026.
Afirma transitioned to V2 transcriptome, improving scalability and result accuracy.
ProSigna LDT launch planned for mid-2026 in the U.S., with positive OPTIMA PRELIM study outcomes and full readout expected mid-2026.
True MRD platform launching in muscle-invasive bladder cancer in 1H 2026, with plans for annual new indications from 2027.
TrueMRD expansion beyond MIBC: key factors?
Capital allocation priorities with $400M cash?
Prosigna's path to share in breast prognostic market?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Veracyte earnings date
Q4 202523 Feb, 2026
Veracyte
Next Veracyte earnings date
Q4 202523 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Veracyte, Inc. develops and commercializes blood tests for the early detection of lung cancer and emphysema. The company offers Veracyte Drug Screening Assay and Veracyte Acute Exacerbation Panel (V-AEP) for the detection of Lung Cancer and Chronic Obstructive Pulmonary Disease (COPD). Its drug screening assays are based on a proprietary approach of analyzing patient genomic data to predict which patients are most likely to have cancer after receiving a lung CT scan. The company markets its products through direct sales force, as well as through clinical laboratory partners, medical practitioners, and directly to patients.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage